Validation Study of the Korean Version of the EORTC QLQ-HDC29
Completed
- Conditions
- Quality of Life After Stem Cell Transplantation
- Registration Number
- NCT01208532
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
The aim of this study is to evaluate the reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer High-dose Chemotherapy module (EORTC HDC-29).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 226
Inclusion Criteria
- Patients who are aged more than 18 years
- Patients who are diagnosed with hematologic malignancies and who are planned to receive high-dose chemotherapy followed by allogeneic or autologous stem cell transplantation (SCT)
- Patients who agree with the informed consent
Exclusion Criteria
- Patients who are unable to complete the questionnaire due to the serious physical or psychological morbidity
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reliability and validity of the Korean version of the EORTC HDC-29 at the patient's hospitalization (before the SCT) and the outpatient clinic (three, six, and 12 months after their SCT) Relaibility; Cronbach's alpha coefficient is used to evaluate the internal consistency.
Validity; Persons's correlation coefficient is used to examine the correlation between similar dimensions of the different questionnaires.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of